Is Eagle Pharmaceuticals (NASDAQ:EGRX) Now a Buy? How Analysts Rate it and Why BidaskScore Upgraded The Stock

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Upgrade

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were upgraded to a solid “Buy” rating by equity analysts working for BidaskScore. EGRX’s previous rating has been discontinued by the firm.

The stock decreased 2.09% or $1.19 during the last trading session, reaching $55.71. About 172,195 shares traded or 14.36% up from the average. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 30.44% since December 5, 2018 and is downtrending. It has underperformed by 30.44% the S&P500.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on February, 27. They expect $0.07 EPS, down 91.86 % or $0.79 from last year’s $0.86 per share. EGRX’s profit will be $956,985 for 198.96 P/E if the $0.07 EPS becomes a reality. After $-0.05 actual EPS reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -240.00 % EPS growth.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $761.62 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 30.73 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

More notable recent Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news were published by: Benzinga.com which released: “Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference – Benzinga” on November 20, 2019, also Seekingalpha.com with their article: “Eagle Pharmaceuticals (EGRX) Presents At RBC Capital Markets 2019 Healthcare Conference – Slideshow – Seeking Alpha” published on May 23, 2019, Seekingalpha.com published: “Eagle Pharmaceuticals Q2 2019 Earnings Preview – Seeking Alpha” on August 07, 2019. More interesting news about Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were released by: Fool.com and their article: “Eagle Pharmaceuticals Inc (EGRX) Q3 2019 Earnings Call Transcript – The Motley Fool” published on November 12, 2019 as well as Finance.Yahoo.com‘s news article titled: “Here’s What Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) P/E Is Telling Us – Yahoo Finance” with publication date: October 02, 2019.